<DOC>
	<DOCNO>NCT00532948</DOCNO>
	<brief_summary>This single arm study assess maximum tolerate dose , dose-limiting toxicity , Xeloda administer concurrently radiation therapy , child newly diagnose diffuse intrinsic brain stem gliomas high grade glioma . Xeloda administer twice daily , start dose 500mg/m2 bid , begin within 24 hour start radiation therapy . Subsequent dose escalation increment 30 % , use standard dose escalation schema . Post-radiation therapy Xeloda continue 2 week break . The anticipated time study treatment 3-12 month , target sample size exceed 30 evaluable patient .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Plus Radiation Therapy Children With Newly Diagnosed Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>patient &gt; =3 &lt; =21 year age ; newly diagnose nondisseminated brainstem glioma nondisseminated high grade glioma ; Karnofsky ( &gt; 16 year ) Lansky ( &lt; 16 year ) Performance Scale &gt; =50 % ; adequate organ function . previous chemotherapy , radiation therapy , immunotherapy bone marrow transplant ; uncontrolled infection ; know DPD deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>